Correlation Between Santhera Pharmaceuticals and Molecular Partners

Can any of the company-specific risk be diversified away by investing in both Santhera Pharmaceuticals and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Santhera Pharmaceuticals and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Santhera Pharmaceuticals Holding and Molecular Partners AG, you can compare the effects of market volatilities on Santhera Pharmaceuticals and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Santhera Pharmaceuticals with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Santhera Pharmaceuticals and Molecular Partners.

Diversification Opportunities for Santhera Pharmaceuticals and Molecular Partners

0.59

Correlation Coefficient

Santhera Pharmaceuticals  Molecular Partners

Very weak diversification

The 3 months correlation between Santhera and Molecular is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Santhera Pharmaceuticals Holdi and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Santhera Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Santhera Pharmaceuticals Holding are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Santhera Pharmaceuticals i.e., Santhera Pharmaceuticals and Molecular Partners go up and down completely randomly.

Pair Corralation between Santhera Pharmaceuticals and Molecular Partners

Assuming the 90 days trading horizon Santhera Pharmaceuticals Holding is expected to generate 0.81 times more return on investment than Molecular Partners. However, Santhera Pharmaceuticals Holding is 1.24 times less risky than Molecular Partners. It trades about 0.01 of its potential returns per unit of risk. Molecular Partners AG is currently generating about -0.04 per unit of risk. If you would invest  1,402  in Santhera Pharmaceuticals Holding on April 22, 2025 and sell it today you would lose (2.00) from holding Santhera Pharmaceuticals Holding or give up 0.14% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Santhera Pharmaceuticals Holdi  vs.  Molecular Partners AG

Santhera Pharmaceuticals

Risk-Adjusted Performance

Very Weak

Over the last 90 days Santhera Pharmaceuticals Holding has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Santhera Pharmaceuticals is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Pair Trading with Santhera Pharmaceuticals and Molecular Partners

The main advantage of trading using opposite Santhera Pharmaceuticals and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Santhera Pharmaceuticals position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.

The idea behind Santhera Pharmaceuticals Holding and Molecular Partners AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.